• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Roche forms alliance with med fusion

Roche forms alliance with med fusion

June 6, 2012
CenterWatch Staff

Roche has formed a strategic alliance with med fusion of Lewisville, Texas, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

As a nationally recognized Roche MCOE, med fusion's molecular diagnostics laboratory will offer physicians and patients some of the newest and advanced molecular technologies, such as Roche's cobas 4800 BRAF V600 Mutation Test, a companion diagnostic approved by the FDA in 2011 to identify patients who are eligible for treatment with the drug Zelboraf (vemurafenib) for inoperable or metastatic melanoma. 

Established in 2002, Roche's MCOE program is designed to create an alliance network that enables non-competing regional laboratories across the U.S. to collaborate and capitalize on scientific knowledge in molecular testing and, in turn, help accelerate the advancement of new test methods and technology.

"Roche is very pleased to welcome med fusion into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president of molecular diagnostics, Roche Diagnostics. "We value their expertise and look forward to working together in implementing molecular technologies in the advancement of personalized medicine."

Of the 35 labs in the U.S. to receive this recognition and join the partnership, med fusion is only one of three based in Texas.

"This relationship with Roche will help keep med fusion on the leading edge of technology and help ensure that we are supporting physicians and patients with the most advanced molecular technologies," said Dr. Thomas Lohmann, chief medical officer, med fusion.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing